Rite Aid, a well-known retail pharmacy chain, filed for Chapter 11 bankruptcy protection in New Jersey recently, according to their official communication.
To recuperate and survive in this competitive retail pharmacy landscape, a transformation in Rite Aid’s business model is necessary. Specifically, it may need to emulate successful strategies employed by its competitors, such as CVS and Walgreens, by enhancing healthcare service delivery, partnering with payers and investing in its digital offerings.
Renowned industry expert, Ash Shehata from KPMG, believes that Rite Aid’s future success depends on whether it sees fit to evolve into an online model, a payer, or a provider. It’s an intense challenge, as the majority of thriving retail pharmacies are incorporating all three avenues.
Shehata also highlights that the aspiration for a pharmacy to be present in every neighborhood is dwindling, especially when customers can have groceries and medicines delivered to their doorstep, thanks to digital advancements.
Along similar lines, Nathan Ray from consulting firm West Monroe underlines the need for close observation of competition in the retail pharmacy sector. Rite Aid’s inability to invest parallely with its peers doesn’t necessarily mandate exact replication of competitors’ strategies, such as pricey acquisitions or developing similar health service offerings, but it does imply the need to deliver similar products or services, perhaps targeting specific geographies or employing different approaches to customer service.
The substantial pharmacy chain, with over 2,000 stores across 17 states, has been battling a downward sales curve, massive debt and consequent lawsuits. Rite Aid had a debt of $3.3 billion but only $135.5 million in cash, according to their recent financial report.
Despite the bankruptcy filing, Rite Aid will continue operations while restructuring finances in a court-supervised process. To aid this, it has procured $3.45 billion. As part of the restructuring plan, Rite Aid proposed closing some “underperforming stores” and potentially selling its pharmacy benefit manager, Elixir, to MedImpact. Both moves would require approval from the bankruptcy judge. The company also recruited Jeff Stein as the new CEO to steer the overhaul.
Read the full story here.